Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murray B Gordon

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 6, 2014
Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDYPamela U Freda, Murray B Gordon, Nicky Kelepouris, et al.
Pituitary|February 22, 2016
Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter studyAmir H Hamrahian, Kevin C J Yuen, Murray B Gordon, et al.
Pituitary|March 30, 2020
An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studiesMaria Fleseriu, Leon Fogelfeld, Murray B Gordon, et al.
Pituitary|September 16, 2019
Development of a novel patient-reported measure for acromegaly: the Acro-TSQMaria Fleseriu, Leon Fogelfeld, Murray B Gordon, et al.
Endocrine|May 17, 2018
Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysisWhitney W Woodmansee, Murray B Gordon, Mark E Molitch, et al.
Pituitary|July 26, 2017
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registryRoberto Salvatori, Murray B Gordon, Whitney W Woodmansee, et al.
Pituitary|March 12, 2021
Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) ProgramBeverly M K Biller, Charlotte Höybye, Paul Carroll, et al.
Journal of the Endocrine Society|May 17, 2023
Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWERBeverly M K Biller, Charlotte Höybye, Jean-Marc Ferran, et al.
Endocrine Connections|November 8, 2022
Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studiesCharlotte Höybye, Beverly M K Biller, Jean-Marc Ferran, et al.
The Journal of Clinical Endocrinology and Metabolism|February 6, 2020
Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 TrialGudmundur Johannsson, Murray B Gordon, Michael Højby Rasmussen, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 6, 2014
Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDYPamela U Freda, Murray B Gordon, Nicky Kelepouris, et al.
Pituitary|February 22, 2016
Revised GH and cortisol cut-points for the glucagon stimulation test in the evaluation of GH and hypothalamic-pituitary-adrenal axes in adults: results from a prospective randomized multicenter studyAmir H Hamrahian, Kevin C J Yuen, Murray B Gordon, et al.
Pituitary|March 30, 2020
An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studiesMaria Fleseriu, Leon Fogelfeld, Murray B Gordon, et al.
Pituitary|September 16, 2019
Development of a novel patient-reported measure for acromegaly: the Acro-TSQMaria Fleseriu, Leon Fogelfeld, Murray B Gordon, et al.
Endocrine|May 17, 2018
Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysisWhitney W Woodmansee, Murray B Gordon, Mark E Molitch, et al.
Pituitary|July 26, 2017
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registryRoberto Salvatori, Murray B Gordon, Whitney W Woodmansee, et al.
Pituitary|March 12, 2021
Pregnancy outcomes in women receiving growth hormone replacement therapy enrolled in the NordiNet® International Outcome Study (IOS) and the American Norditropin® Studies: Web-Enabled Research (ANSWER) ProgramBeverly M K Biller, Charlotte Höybye, Paul Carroll, et al.
Journal of the Endocrine Society|May 17, 2023
Long-term Effectiveness and Safety of GH Replacement Therapy in Adults ≥60 Years: Data From NordiNet® IOS and ANSWERBeverly M K Biller, Charlotte Höybye, Jean-Marc Ferran, et al.
Endocrine Connections|November 8, 2022
Reduced CV risk with long-term GH replacement in AGHD: data from two large observational studiesCharlotte Höybye, Beverly M K Biller, Jean-Marc Ferran, et al.
The Journal of Clinical Endocrinology and Metabolism|February 6, 2020
Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 TrialGudmundur Johannsson, Murray B Gordon, Michael Højby Rasmussen, et al.
Pageof 4